United States Bacterial Vaginosis Drug Revenue Is Nearly 162 M USD In 2016
Warning: date() expects parameter 2 to be long, string given in /www/wwwroot/www.globalinforesearch.com/static/themes/default/info_detail.php on line 32
In the last several years, United States market of Bacterial Vaginosis Drug developed stable, with an average growth rate of 2.7%. In 2016, United States revenue of Bacterial Vaginosis Drug is nearly 162 M USD.
The United States average price of Bacterial Vaginosis Drug is in the fluctuating trend, from 26.6/Unit in 2012 to 26.8 USD/Unit in 2016.
The classification of Bacterial Vaginosis Drug includes Clindamycin, Metronidazole, Tinidazole and others, and the proportion of Metronidazole in 2016 is about 40 and the revenue proportion of Clindamycin is about 27%.
Bacterial Vaginosis Drug is widely used in Hospital, Drug Store and other field. The most proportion of Bacterial Vaginosis Drug is in Drug Store, and the sales proportion in 2016 is about 53%.
South Atlantic is the largest consumption place, with a consumption market share nearly 24% in 2016. Following South Atlantic, Pacific is the second largest consumption place with the consumption market share of 23%.
Market competition is not intense. Pfizer, Teva, Perrigo, Mylan, Lupin Pharmaceuticals etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.